OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

October 4th 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Thomas on Potential Biomarkers of Response to Berzosertib/Topotecan in SCLC

October 4th 2021

Anish Thomas, MD, discusses potential biomarkers of response to the combination of berzosertib plus topotecan in patients with relapsed, platinum-resistant small cell lung cancer.

Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLC

October 4th 2021

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.

Dr. Spira on the Role of Frontline Brigatinib in ALK+ NSCLC

October 4th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Dr. Shah on the FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL

October 1st 2021

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

October 1st 2021

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

October 1st 2021

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Chi on Future Research Efforts With PARP Inhibitors in Metastatic Prostate Cancer

October 1st 2021

Kim Chi, MD, discusses future research directions with PARP inhibitors in metastatic prostate cancer.

Dr. Sia on a Novel Classification System in Intrahepatic Cholangiocarcinoma

October 1st 2021

Daniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.

Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLC

September 30th 2021

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Dr. Hamid on the Integration of TIL-Based Therapy Into Melanoma

September 30th 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Dr. Dholaria on the Rationale for the MagnetisMM-1 Trial in Multiple Myeloma

September 30th 2021

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

September 30th 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Dr. Hurvitz on the Rationale for the coopERA Breast Cancer Trial in ER+/HER2- Breast Cancer

September 29th 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Weiss on the Efficacy Results of the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

September 29th 2021

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29th 2021

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Dr. Baz on the Utility of Venetoclax in Heavily Pretreated Multiple Myeloma

September 29th 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Dr. Lustberg Discusses Ongoing Research in Breast Cancer

September 28th 2021

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.